CD274 and small cell lung carcinoma: In patients with ES-SCLC, the IMpower133 clinical trial, studying the treatment of atezolizumab in combination with carboplatin and etoposide, the primary endpoints of PFS and OS were met, with improved survival for patients treated with atezolizumab without evaluation of PD-L1 status (81).